‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight

Live updates

1. 1h ago

   Eli Lilly Triple-G Trial Shows 12.7% Weight Loss On Lowest Dose

   Trial patients taking the lowest dose of Eli Lilly's experimental triple-hormone-receptor agonist retatrutide lost 12.7 percent of their body weight, according to recent updates from clinical studies. The drug targets three metabolic receptors including GLP-1, GIP, and glucagon, earning it the label of a next-generation obesity treatment. Across clinical evaluations, the drug has delivered substantial reductions, with average weight loss reaching about 50 pounds in certain contexts. Additionally, Eli Lilly reported data on combination regimens like EloraTZP, showing greater weight loss and A1C reduction compared to existing therapies in adults with obesity and type 2 diabetes.

   Why it matters

   Retatrutide represents an evolution in cardiometabolic drug development by attacking multiple biological pathways simultaneously rather than relying on single-receptor mechanisms. Eli Lilly expects to submit the treatment to the Food and Drug Administration for approval early next year as clinical trials draw to a close. These advancements build upon earlier successes of GLP-1 medications, pushing efficacy boundaries further for patients managing obesity and type 2 diabetes.

   What is confirmed

   • Patients on the lowest dose of Eli Lilly's triple-G drug retatrutide lost 12.7 percent of their weight in trial evaluations.
   • Retatrutide is the first drug of its kind to target three metabolic receptors, specifically GLP-1, GIP, and glucagon.
   • Eli Lilly plans to submit retatrutide to the FDA for approval early next year as clinical trials conclude.
   • Lilly's EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1C reduction compared to tirzepatide 15 mg in adults with obesity and type 2 diabetes.

   Still unconfirmed

   • Retatrutide delivers an average weight loss of 50 pounds.

   What to watch next

   • Submission of retatrutide to the FDA for approval early next year
   • Further disclosure of late-stage clinical trial data by Eli Lilly
   Sources used for this update (11)

   1. The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
   2. CNBC — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
   3. Eli Lilly — Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
   4. Reuters — Experimental Lilly combination drug tops Zepbound in weight-loss trial
   5. USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
   6. New York Post — ‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
   7. New Scientist — ‘Astonishing’ weight loss when GLP-1 drug used with second medication
   8. nypost.com — Even on the lowest dose of 'triple G' drug patients lost ...
   9. WSJ — Lilly’s Next-Gen Obesity Drug Helps People Lose Even More Weight in Study
   10. jen.jiji.com — Timofeeva and the watch stolen in the locker room: "I had left it unattended for 10 minutes..."
   11. pharmaphorum.com — Lilly fleshes out triple G data in diabetes and obesity
   confidence 95%